描述

Nanoparticles can be engineered with distinctive compositions, 尺寸, shapes, and surface chemistries to enable novel techniques in a wide range of biological applications. The global nanoparticles in biosciences market is set to increase by US$ 47.9 十亿来自 2022 到 2028, 代表复合年增长率 (复合年增长率) 的 7.7% 在预测期内.

该报告提供了该时期的最新市场规模数据 2018-2021 并预测到 2028 covering key market aspects like sales value for nanoparticles in biosciences. The global nanoparticles in biosciences market is segmented on the basis of product, 和地区. 根据产品, the global nanoparticles in biosciences market has been segmented into drug delivery systems, drug development and formulation, 其他的. 在这些当中, the drug delivery systems segment was accounted for the highest revenue generator in 2021. 从地理上来说, the global nanoparticles in biosciences market has been segmented into Asia Pacific, 欧洲, 北美, 世界其他地区 (排). North America is estimated to account for the largest share of the global nanoparticles in biosciences market.

The global nanoparticles in biosciences market is highly competitive. The key players in the nanoparticles in biosciences market include Bristol Myers Squibb Company (BMS), Camurus AB, F. Hoffmann-La Roche AG, 葛兰素史克公司 (葛兰素史克), Merck KGaA, NanoCarrier Co. 有限公司, Novartis International AG.

该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the nanoparticles in biosciences market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.

报告范围

产品: drug delivery systems, drug development and formulation, 其他的
地区: 亚太地区, 欧洲, 北美, 世界其他地区 (排)
考虑的年数: 本报告涵盖期间 2018 到 2028

利益相关者的主要好处

– Get a comprehensive picture of the global nanoparticles in biosciences market
– 精准定位增长领域和投资趋势

目录

部分 1. 介绍
– 研究范围
– 学习时段
– 地理范围
– 研究方法论
部分 2. Nanoparticles in biosciences market overview
部分 3. 按产品划分的市场细分
– Drug delivery systems
– Drug development and formulation
– 其他的
部分 4. 按地区划分的市场细分
– 亚太地区
– 欧洲
– 北美
– 世界其他地区 (排)
部分 5. 重点企业
– Bristol Myers Squibb Company (BMS)
– Camurus AB
– F. Hoffmann-La Roche AG
– 葛兰素史克公司 (葛兰素史克)
– Merck KGaA
– NanoCarrier Co., 有限公司.
– Novartis International AG
关于StrategyHelix
免责声明